FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
Intellia Therapeutics (NTLA) announced the FDA accepted and granted priority review to its BLA for lonvoguran ziclumeran, a CRISPR-based therapy for hereditary angioedema (HAE). A decision is expected by March 2027. The therapy showed an 87% reduction in attacks in a phase III study. NTLA shares have risen 41.7% year-to-date. The company also has another CRISPR therapy, nexiguran ziclumeran, in development with Regeneron (REGN).
How this was made
The 30-second read
Why it matters
The FDA's priority review signals confidence in the data and accelerates the path to market, likely prompting a price rally.
Market read
Regulatory approval timeline is a key catalyst for NTLA; investors will watch the March 2027 decision closely.
What to watch
Potential competition from other gene‑editing platforms and the long timeline to commercial launch.
Background
Intellia Therapeutics (NTLA) is developing the first in‑vivo CRISPR therapy for hereditary angioedema, with a Phase III trial showing an 87% attack reduction.
Ticker impact
FDA accepted Intellia's BLA for lonvo‑z and granted priority review, with a decision expected March 10, 2027.
Short‑term upside as investors price in the chance of approval; potential rally if data remain strong.
Priority review is a rare, high‑impact event for a biotech; the market typically reacts favorably to such FDA actions.
Market effects
May lift sentiment for CRISPR‑based gene‑editing biotech sector.
U.S. biotech stocks could see modest gains.
Highlights progress of in‑vivo CRISPR therapies, relevant to global biotech investors.
Counterpoint
If the Phase III data are later questioned, the priority review could be a false positive for price.
Key entities
- CompanyIntellia Therapeutics
Biotech developer of CRISPR‑based therapies.
- RegulatorFDA
U.S. Food and Drug Administration granting priority review.
